Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Denosumab is a fully human monoclonal antibody to receptor activator of nuclear factor kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the principal regulator of osteoclastic bone resorption. Postmenopausal osteoporosis (PMO) is a systemic skeletal disease associated with high levels of RANKL, resulting in a high rate of bone remodeling and an imbalance of bone resorption over bone formation. By inhibiting RANKL in women with PMO, denosumab reduces the rate of bone remodeling, thereby increasing bone mineral density, improving bone strength, and reducing the risk of fractures. In clinical trials of women with osteoporosis and low bone mineral density, denosumab has been well tolerated, with overall rates of adverse events and serious adverse events in women treated with denosumab similar to those receiving placebo. In the largest clinical trial of denosumab for the treatment of women with PMO, there was a significantly greater incidence of cellulitis reported as a serious adverse event, with no difference in the overall incidence of cellulitis, and a significantly lower incidence of the serious adverse event of concussions with denosumab compared with placebo. The evidence supports a favorable balance of benefits versus risks of denosumab for the treatment of PMO. Assessments of the long-term safety of denosumab are ongoing. Denosumab 60 mg subcutaneously every 6 months is an approved treatment for women with PMO who are at high risk for fracture.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149
Self-citationDenosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986 · cited 1×
“…risk of atrial fibrillation as a serious adverse event has been reported in a single randomized, placebo-controlled trial of zoledronic acid, 74 another potent antiresorptive agent, suggesting the possibility that this might be a class effect of bisphosphonates Notes: These are listed as…”
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
RANK is essential for osteoclast and lymph node development.
Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478
Denosumab in postmenopausal women with low bone mineral density.
McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228
Self-citationParfitt, A. M. (1994) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240550303 · Cited by 1,001 · cited 1×
“025 mm(3) and a lifespan of about 6–9 months, resulting in a turnover of approximately 10% of the entire skeleton each year.(19) BMUs can be identified microscopically as tiny pits on the surface of trabecular bone (the type of bone in the interior of vertebral bodies and inside the ends of long bones) and tunnels (Ha…”
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825 · cited 13×
“25 Recombinant OPG prevents bone loss in ovariectomized rats 25 and causes nonlethal osteopetrosis in normal mice.”
InfluentialKearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Li, Y., Toraldo, G., Li, A., Yang, X., Zhang, H., Qian, W.-P., & Weitzmann, M. N. (2007) · Blood · doi:10.1182/blood-2006-07-037994 · Cited by 520 · cited 1×
“OPG is expressed by mature B cells.(57) However, a small permissive level of RANKL and RANK in transgenic rats is associated with normal lymph node development(58,59) and inhibition of RANKL in adult humans has not been shown to adversely affect measured parameters of immune function.”
The effect of a single dose of osteoprotegerin in postmenopausal women.
Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484
Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells
Loser, K., Mehling, A., Loeser, S., Apelt, J., Kuhn, A., Grabbe, S., Schwarz, T., Penninger, J. M., & Beissert, S. (2006) · Nature Medicine · doi:10.1038/nm1518 · Cited by 402 · cited 1×
“60 The finding that cutaneous RANKL expression suppresses inflammation of the skin in mice 61 suggests the possibility that RANKL inhibition in humans might lead to an enhanced inflammatory response, providing a rationale for the observation of some of the dermatological untoward occurrences…”
Stolina, M., Dwyer, D., Ominsky, M. S., Corbin, T., Van, G., Bolon, B., Sarosi, I., McCabe, J., Zack, D. J., & Kostenuik, P. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.11.7497 · Cited by 63
The effects of osteoprotegerin on the mechanical properties of rat bone.
Ross, A. B., Bateman, T. A., Kostenuik, P. J., Ferguson, V. L., Lacey, D. L., Dunstan, C. R., & Simske, S. J. (2001) · Journal of Materials Science: Materials in Medicine · doi:10.1023/a:1011229324412 · Cited by 39 · cited 1×
“In young male rats, RANKL inhibition increases bone mineralization and improves mechanical strength in the femur.(26) These preclinical studies and others with similar findings paved the way for the study of RANKL inhibition in humans.”
Cited by
Bone Morphogenetic Protein-2 in Development and Bone Homeostasis
Halloran, D., Durbano, H. W., & Nohe, A. (2020) · Journal of Developmental Biology · doi:10.3390/jdb8030019 · Cited by 348
RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass
Bonnet, N., Bourgoin, L., Biver, E., Douni, E., & Ferrari, S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125915 · Cited by 314
“This argues for a specific positive action of Dmab on muscles, which could contribute to the 21% reduction of falls previously observed in the FREEDOM trials (11).”
InfluentialBisphosphonates as a supplement to exercise to protect bone during long-duration spaceflight
LeBlanc, A., Matsumoto, T., Jones, J., Shapiro, J., Lang, T., Shackelford, L., Smith, S. M., Evans, H., Spector, E., Ploutz-Snyder, R., et al. (2013) · Osteoporosis International · doi:10.1007/s00198-012-2243-z · Cited by 234
Metadata
- Authors
- Lewiecki, E. M.
- Venue
- Drug, Healthcare and Patient Safety
- Publisher
- Informa UK Limited
- Published
- 2011-12
- Volume
- 3
- Pages
- 79
- ISSN
- 1179-1365 (ISSN-L)
- OpenAlex
- W2120394988
- Cited by
- 41
- References
- 15
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.